Shenzhen Zhongge Biotechnology Co. Ltd. has identified translation initiation factor 2B (EIF2B) activators reported to be useful for the treatment of autoimmune disease, cancer, viral infection, neurodegeneration, metabolic diseases, and eye, dermatological and inflammatory disorders, among others.

Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, dyslipidemia and obesity.

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has divulged stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, Alzheimer’s disease, pulmonary fibrosis, heart failure, infections, psoriasis, Sjögren’s syndrome and systemic lupus erythematosus, among others.

Shenzhen Zhongge Biotechnology Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, liver, cardiovascular, inflammatory, renal, metabolic and neuroinflammatory disorders.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and derived PROTAC compounds reported to be useful for the treatment of autoimmune disorders, inflammatory disorders, cancer, transplant rejection and more.

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and/or degraders reported to be useful for the treatment of cancer, psoriasis, systemic lupus erythematosus, osteoarthritis, graft-vs.-host disease, rheumatoid arthritis, irritable bowel syndrome and chronic obstructive pulmonary disease, among others.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed translation initiation factor 2B (eIF2B) activators reported to be useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, and autoimmune, eye, renal and dermatological disorders, among others.

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors reported to be useful for the treatment of cancer, obesity, atherosclerosis, type 1 diabetes, type 2 diabetes, neurodegeneration, metabolic syndrome and inflammatory bowel disease, among others.